2Q 2026
Earnings Presentation

July 29, 2026

GE HealthCare

Forward-looking statements and additional information

This presentation contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,” “forecast,” “target,” “guidance,” “outlook,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about our business and expected financial performance, financial condition, and results of operations, including revenue, revenue growth, profit, taxes, earnings per share, and cash flows, and our outlook and medium-term financial targets; changes to our business, operating, and leadership structure and related impacts; the impacts of macroeconomic and market conditions, including the impact of tariffs and other trade restrictions, and volatility on our business, operations, financial results, and financial position and on supply chains and the world economy; our receipt of future tariff refunds and the timing and amount thereof; our cost structure; our funding and liquidity; the impacts on our business of manufacturing, sourcing, and supply chain management; the impacts on our business of international conflicts, including the Russia and Ukraine conflict and conflicts in the Middle East; share repurchases; risks related to foreign currency exchange, interest rates, and commodity and key material price volatility and availability; operational performance; demand in the global markets in which we operate; and our strategy, innovation, and acquisitions and investments. These forward-looking statements involve risks and uncertainties, many of which are beyond our control. Factors that could cause our actual results to differ materially from those described in our forward-looking statements include, but are not limited to, operating in highly competitive markets; global geopolitical and economic instability, including as a result of changes in trade and tariff policy, and international conflicts and tensions, including between Ukraine and Russia, in the Middle East, and in other regions; public health crises, epidemics, and pandemics, and their effects on our business; changes in or elimination of government subsidies, and changes in third-party and government reimbursement processes, rates, and contractual relationships, including related to government shutdowns, and changes in the mix of public and private payers; demand for our products, services, or solutions and factors that affect that demand; developments in the market in China; our ability to control increases in healthcare costs and any subsequent effect on demand for our products, services, or solutions; our ability to successfully complete strategic transactions; the actions or inactions of third parties with whom we partner and the various collaboration, licensing, and other partnerships and alliances we have with third parties; the impacts related to our increasing focus on and investment in cloud, edge computing, artificial intelligence, and software offerings; management of our supply chain and our ability to cost-effectively secure the materials we need to operate our business; disruptions in our operations; the impact of potential information technology, cybersecurity, or data security breaches; maintenance and protection of our intellectual property rights, as well as maintenance of successful research and development efforts with respect to commercially successful products and technologies; our ability to attract and/or retain key talent and qualified employees; increasing attention to sustainability matters; compliance with the various legal, regulatory, tax, privacy, and other laws to which we are subject, such as the Foreign Corrupt Practices Act and similar anti-corruption and anti-bribery laws globally, and related changes, claims, inquiries, investigations, or actions; the impact of potential product liability claims or potential litigation, arbitration, or similar proceedings; and our level of indebtedness and the impact of complying with the covenants and other terms of our debt instruments on our business. Please also see Item 1A, “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission and any updates or amendments we make in future filings. There may be other factors not presently known to us or which we currently consider to be immaterial that could cause our actual results to differ materially from those projected in any forward-looking statements we make. We do not undertake any obligation to update or revise our forward-looking statements except as required by applicable law or regulation.

Non-GAAP Financial Measures

This presentation contains non-GAAP financial measures. See appendix for definitions, reconciliations of historical GAAP to non-GAAP financial measures, and for more information on our Outlook.

Financial Rounding

Certain columns and rows throughout this document may not sum due to the use of rounded numbers. Percentages presented are calculated from the underlying whole-dollar amounts.

Product Status

Not all products or features are available in all markets. The information presented here may involve technologies and concepts in development that are not products and may never become products. For Technology in Development, the technologies or concepts are not being offered for sale, and are not cleared or approved by the U.S. FDA or any other global regulator for commercial availability.

2Q 2026 Update

- Revenue growth led by strength in PDx and AIS
- Record orders, book-to-bill and backlog; healthy demand across all segments and geographies for our differentiated products and solutions
- Focused actions underway to strengthen execution and improve PCS performance; reviewing strategic options to maximize long-term value
- Progress with Heartbeat to drive growth, price and productivity; delivered strong YoY Adjusted EPS* growth
- Reaffirms full year 2026 guidance

The **combination of MIM Software and our growing MICT portfolio** is a differentiator helping win customer deals and delivering meaningful clinical value in high-growth areas such as radiation oncology

*Non-GAAP financial measure.
Note: Not all products available in all regions.

Advancing our growth strategy

Precision care

D3: Smart devices and drugs, across disease states, enabled by digital, AI and software solutions

- Signed **~$500M Care Alliance with Catholic Health** encompassing several care areas and services support
- Strengthened **theranostics collaboration with leading academic in Germany;** fully integrated portfolio with latest NPIs
- Robust **U.S. radiopharmaceutical growth** across all tracers; Flyrcado on track for a $500M+ annual opportunity and Vizamyl for $200M+ by 2028

Growth acceleration

Positioned to accelerate top-line growth with innovation over the medium-term

- Orders growth driven by **strong commercial execution enabled by Heartbeat, and customer adoption of NPIs** across all segments and regions
- **New wave of innovation** timelines on track
- **Phase 2/3 trial for Gadolinium-free MR contrast agent progressing well** with high patient recruitment in U.S. and Europe

Business optimization

Focus on enhancing customer satisfaction and margin expansion

- Incremental **price and cost actions** to offset inflation beginning to take effect
- **Leveraging AI** to improve productivity and simplify work, enhance inventory planning and optimize production performance to deliver for customers
- **Consolidation of new AIS segment and Global Markets region**(1), creating a more connected, end-to-end imaging ecosystem and enhancing commercial capabilities

Note: Not all products available in all regions.
(1)Subject to information and/or consultation with employees and their representatives as required

2Q 2026 Consolidated performance summary

Revenues	Organic orders growth**	Adjusted EBIT* and Adjusted EBIT margin*	Adjusted EPS*	Free cash flow*
$5.3B	11.1% YoY	$750M	$1.13	$68M
3.5% YoY Organic growth*(1)	Book-to-Bill** **1.15x**	**14.2%** Margin (40) bps YoY	**6.6%** YoY	**$61M** YoY
	Backlog** **$23.9B**	*Includes the benefit of refunds for IEEPA tariffs incurred in 2026 of $23M*	*Includes the benefit of refunds for IEEPA tariffs incurred in 2026 of $0.04*	*Includes the benefit of refunds for IEEPA tariffs incurred in 2025 & 2026 of $107M*

Adjusted EBIT and Adjusted EPS* results exclude the benefit of refunds for tariffs incurred in 2025 of $106M and $0.18, respectively*

*Non-GAAP financial measure. See appendix for reconciliation of GAAP to non-GAAP financial measures.
**See appendix for Key Performance Indicator definition
(1) Figures represent comparison to 2Q 2025 on an Organic* basis

2Q Adjusted EBIT margin* performance YoY



Heartbeat driving commercial execution, price and productivity helping to offset headwinds

*Non-GAAP financial measure. See appendix for reconciliation of GAAP to non-GAAP financial measures.

2Q 2026 Advanced Imaging Solutions results

	2Q 2025	2Q 2026	YoY change
Revenues	$3,493M	$3,771M	5.0%*(1)
Segment EBIT	$455M	$525M	15.4%
Segment EBIT margin	13.0%	13.9%	90 bps

Highlights

- Solid Organic revenue growth* YoY driven by strength in CardioVascular & Interventional Solutions, CT and Molecular Imaging
- EBIT performance benefited from volume growth and price, partially offset by cost inflation
- Combination of higher margin NPIs and elevated clinical and commercial expertise driving growth



World's first installation of **StarGuide™ GX**(2) at University Hospital Essen's Nuclear Medicine Center of Excellence in Germany, reinforcing our position as a leader in theranostics

*Non-GAAP financial measure. See appendix for reconciliation of GAAP to non-GAAP financial measures.
(1) Figures represent comparison to 2Q 2025 on an Organic* basis.
(2) CE marked. Not available for sale in all regions. Not approved or cleared by the U.S. FDA. Not available for sale in the U.S.

2Q 2026 Pharmaceutical Diagnostics results

	2Q 2025	2Q 2026	YoY change
Revenues	$729M	$843M	14.6%*(1)
Segment EBIT	$213M	$250M	16.9%
Segment EBIT margin	29.3%	29.6%	30 bps

Highlights

- Robust YoY Organic revenue growth* driven by volume and price in contrast media and U.S. radiopharmaceutical products
- EBIT margin increased YoY due to strong volume and price, partially offset by planned investments to support new products and innovation pipeline
- Expect continued growth driven by global contrast media demand and scaling U.S. radiopharmaceutical momentum across disease states



Growing adoption of **Vizamyl™ (flutemetamol F 18 injection)** expands access to Alzheimer's disease imaging; reflects increased adoption of novel therapies

*Non-GAAP financial measure. See appendix for reconciliation of GAAP to non-GAAP financial measures.
(1) Figures represent comparison to 2Q 2025 on an Organic* basis.
Note: Not all products and features are available in all markets.

2Q 2026 Patient Care Solutions results

	2Q 2025	2Q 2026	YoY change
Revenues	$778M	$675M	(13.5)%*(1)
Segment EBIT	$60M	$(26)M	(143.0)%
Segment EBIT margin	7.7%	(3.8)%	(1,150) bps

Highlights

- Revenue and EBIT declined YoY, predominantly impacted by operational and fulfillment challenges
- Strong 1H'26 orders reinforcing healthy demand
- Expect 2H'26 supply improvement and U.S. FDA clearance of new premium anesthesia product

Strong monitoring orders momentum, including **CARESCAPE Canvas**TM, fueled by large U.S. enterprise wins supporting hospital efficiency, clinical flexibility, and care transformation

*Non-GAAP financial measure. See appendix for reconciliation of GAAP to non-GAAP financial measures.
(1) Figures represent comparison to 2Q 2025 on an Organic* basis.

Cash performance and capital deployment priorities

2Q 2026 Free cash flow*



Capital deployment highlights

- Delivered $68M in Free cash flow* in the quarter
- YoY Free cash flow* increased primarily due to tariff refunds, partially offset by working capital investments and capital expenditures to support growth
- Delivered $216M in shareholder returns: ~$200M in share repurchases and ~$16M in dividends; $500 million remaining in the Board authorized share repurchase program

* Non-GAAP financial measure. See appendix for reconciliation of GAAP to non-GAAP financial measures.

Reaffirms 2026 Outlook

	2025A	2026E
Organic Revenue Growth*(1)	3.5%	3.0% - 4.0%
Adjusted EBIT Margin*	15.3%	15.4% - 15.7% 10 – 40 bps
Adjusted ETR*	20.2%	20.0% - 21.0%
Adjusted EPS*	$4.59	$4.80 - $5.00 4.6% - 9.0%
Free Cash Flow*	$1.5B	~$1.6B

Assumptions:

- Reflects healthy capital equipment environment
- Continue to expect year-over-year decline in China revenue; no material impact to revenue from global memory chip shortage
- ~50 bps FX benefit to revenue based on current rates
- Continue to expect ~$250M of cost inflation; expect to offset more than half of impact with price and cost actions

Note: The benefits of refunds for tariffs incurred in 2025 are not included in guidance for 2026 Adjusted EBIT margin* ($106 million to date) and Adjusted EPS* ($0.18 to date). The benefits of refunds for tariffs incurred in 2026 are included in guidance for 2026 Adjusted EBIT margin* ($23 million) and Adjusted EPS* ($0.04). We do not expect a material benefit to Adjusted EBIT margin* and Adjusted EPS* from additional refunds for tariffs incurred in 2026.

* Non-GAAP financial measure. See appendix for reconciliation of historical GAAP to non-GAAP financial measures and for more information on our Outlook.
(1) Figures represent comparison to previous year on an Organic* basis.

AIS + D3 + Heartbeat positions GE HealthCare to win in the market



Differentiated products – Advancing new wave of innovation aligned to customers needs, driving higher win rate and margin growth

Commercial execution – Strengthening commercial execution through deeper clinical expertise, expanded service capabilities and enterprise problem solving

Heartbeat enablement – Leveraging Heartbeat to continuously improve execution, translating customer needs into solutions that drive growth

AIS contributed significantly to record organic orders growth in 2Q’26, underpinned by streamlined segment execution**

**See appendix for Key Performance Indicator definition

Connecting customer goals to care transformation

Combination of differentiated products, commercial team strength, and field services enables stronger partnerships

Trusted healthcare solutions provider

Catholic Health

$500M, 10-year Care Alliance
Supporting cardiology growth
Modernized equipment, digital solutions + services support

GE HealthCare

D3: Integrated, disease-focused solutions with new wave of innovation
Heartbeat: Disciplined, collaborative execution

University Hospital Essen

Nuclear medicine center of excellence
Theranostics platform for more precise cancer care
Advanced imaging + workflow solutions

Uniquely positioned to deliver precision care across multiple disease states

Summary

- Business momentum reflected in record order intake and healthy end market demand
- Meaningful progress in new wave of innovation
- Leveraging Heartbeat to drive commercial execution and business performance while managing inflation impact
- Adjusted EPS* exceeded our expectations
- Outlook for 2026 reflects confidence in business fundamentals

World's first implementation of **Allia™ Moveo** for pediatric interventional radiology at UW Health in Madison, WI, a longtime GE HealthCare partner

*Non-GAAP financial measure.

GE HealthCare

Q&A

Upcoming event

Wells Fargo Healthcare Conference	September 9, 2026

Appendix

Organic Revenue*

($ in millions)

Unaudited	For the three months ended June 30			For the six months ended June 30		
	2026	2025	% change	2026	2025	% change
Total revenues	**$ 5,295**	**$ 5,007**	**5.7 %**	**$ 10,425**	**$ 9,784**	**6.6 %**
Less: Acquisitions[(1)]	62	—		122	1	
Less: Dispositions[(2)]	—	—		—	—	
Less: Foreign currency exchange	51	—		205	—	
Organic revenue*	**$ 5,182**	**$ 5,007**	**3.5 %**	**$ 10,098**	**$ 9,783**	**3.2 %**

(1) Represents revenues attributable to acquisitions from the date the Company completed the transaction through the end of four quarters following the transaction, excluding the impact of Foreign currency exchange already captured in lines elsewhere.

(2) Represents revenues attributable to dispositions for the four quarters preceding the disposition date.

*Non-GAAP financial measure.

Segment Organic Revenue*

($ in millions)

Unaudited	For the three months ended June 30			For the six months ended June 30		
	2026	2025	% change	2026	2025	% change
AIS revenues	**$ 3,771**	**$ 3,493**	**7.9 %**	**$ 7,410**	**$ 6,872**	**7.8 %**
Less: Acquisitions[(1)]	62	—		72	—	
Less: Dispositions[(2)]	—	—		—	—	
Less: Foreign currency exchange	41	—		156	—	
AIS Organic revenue*	**$ 3,668**	**$ 3,493**	**5.0 %**	**$ 7,182**	**$ 6,872**	**4.5 %**
PDx revenues	**$ 843**	**$ 729**	**15.6 %**	**$ 1,612**	**$ 1,362**	**18.4 %**
Less: Acquisitions[(1)]	—	—		50	1	
Less: Dispositions[(2)]	—	—		—	—	
Less: Foreign currency exchange	8	—		35	—	
PDx Organic revenue*	**$ 835**	**$ 729**	**14.6 %**	**$ 1,527**	**$ 1,360**	**12.3 %**
PCS revenues	**$ 675**	**$ 778**	**(13.3)%**	**$ 1,379**	**$ 1,531**	**(10.0)%**
Less: Acquisitions[(1)]	—	—		—	—	
Less: Dispositions[(2)]	—	—		—	—	
Less: Foreign currency exchange	2	—		14	—	
PCS Organic revenue*	**$ 673**	**$ 778**	**(13.5)%**	**$ 1,365**	**$ 1,531**	**(10.9)%**

(1) Represents revenues attributable to acquisitions from the date the Company completed the transaction through the end of four quarters following the transaction, excluding the impact of Foreign currency exchange already captured in lines elsewhere.

(2) Represents revenues attributable to dispositions for the four quarters preceding the disposition date.

*Non-GAAP financial measure.

Adjusted EBIT*

($ in millions)

Unaudited	For the three months ended June 30 2026	2025	% change	For the six months ended June 30 2026	2025	% change
Net income attributable to GE HealthCare	**$ 561**	**$ 486**	**15.5 %**	**$ 950**	**$ 1,049**	**(9.5)%**
Add: Interest and other financial charges – net	114	113		210	224	
Add: Non-operating benefit (income) costs	(45)	(73)		(96)	(148)	
Less: Benefit (provision) for income taxes	(119)	(113)		(213)	(216)	
Less: Net (income) loss attributable to noncontrolling interests	(13)	(14)		(35)	(39)	
EBIT*	**761**	**653**	**16.7 %**	**1,312**	**1,380**	**(5.0)%**
Add: Restructuring costs[(1)]	27	18		76	40	
Add: Acquisition and disposition-related charges (benefits)[(2)]	11	7		46	15	
Add: Spin-Off and separation costs and other adjustments[(3)]	(5)	5		(2)	29	
Add: (Gain) loss on business and asset dispositions[(4)]	—	5		—	(5)	
Add: Amortization of acquisition-related intangible assets	61	40		108	75	
Add: Investment revaluation (gain) loss[(5)]	—	1		8	(92)	
Less: Tariff refunds[(6)]	106	—		106	—	
Adjusted EBIT*	**$ 750**	**$ 729**	**2.9 %**	**$ 1,440**	**$ 1,443**	**(0.2)%**
Net income margin	**10.6 %**	**9.7 %**	**90 bps**	**9.1 %**	**10.7 %**	**(160) bps**
Adjusted EBIT margin*	**14.2 %**	**14.6 %**	**(40) bps**	**13.8 %**	**14.8 %**	**(90) bps**

(1) Consists of severance, facility closures, and other charges associated with restructuring programs.
(2) Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions.
(3) Costs and other adjustments related to the Spin-Off and separation from GE, including system implementations, audit and advisory fees, legal entity separation, Founders Grant equity awards, separation agreements with GE, and other one-time costs.
(4) Consists of gains and losses resulting from the sale of assets and investments.
(5) Primarily relates to valuation adjustments for equity investments and for the six months ended June 30, 2025, includes the impact from the revaluation of our existing 50% interest in NMP as part of the acquisition transaction.
(6) Consists of the pre-tax impact of refunds pertaining to IEEPA tariffs incurred in the year ended December 31, 2025.

* Non-GAAP financial measure.

Adjusted Net Income*

($ in millions)

Unaudited	For the three months ended June 30 2026	2025	% change	For the six months ended June 30 2026	2025	% change
Net income attributable to GE HealthCare	**$ 561**	**$ 486**	**15.5 %**	**$ 950**	**$ 1,049**	**(9.5)%**
Add: Non-operating benefit (income) costs	(45)	(73)		(96)	(148)	
Add: Restructuring costs(1)	27	18		76	40	
Add: Acquisition and disposition-related charges (benefits)(2)	11	7		46	15	
Add: Spin-Off and separation costs and other adjustments(3)	(5)	5		(2)	34	
Add: (Gain) loss on business and asset dispositions(4)	—	5		—	(5)	
Add: Amortization of acquisition-related intangible assets	61	40		108	75	
Add: Investment revaluation (gain) loss(5)	—	1		8	(92)	
Less: Tariff refunds(6)	106	—		106	—	
Add: Tax effect of reconciling items(7)	11	(1)		(8)	(1)	
Add: Spin-Off and other tax adjustments(8)	—	—		(7)	(18)	
Adjusted net income*	**$ 515**	**$ 487**	**5.6 %**	**$ 967**	**$ 951**	**1.7 %**

(1) Consists of severance, facility closures, and other charges associated with restructuring programs.

(2) Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions.

(3) Costs and other adjustments related to the Spin-Off and separation from GE, including system implementations, audit and advisory fees, legal entity separation, Founders Grant equity awards, separation agreements with GE, and other one-time costs. For the six months ended June 30, 2025, an adjustment is included to eliminate the associated impact on Net (income) loss attributable to noncontrolling interests for applicable costs that impact earnings attributable to noncontrolling interests.

(4) Consists of gains and losses resulting from the sale of assets and investments.

(5) Primarily relates to valuation adjustments for equity investments and for the six months ended June 30, 2025, includes the impact from the revaluation of our existing 50% interest in NMP as part of the acquisition transaction.

(6) Consists of the pre-tax impact of refunds pertaining to IEEPA tariffs incurred in the year ended December 31, 2025. The associated tax effect is presented on the Tax effect of reconciling items line. The net of tax impact of tariff refunds is $81 million for the three and six months ended June 30, 2026.

(7) The tax effect of reconciling items is calculated using the statutory tax rate, taking into consideration the nature of the items and the relevant taxing jurisdiction.

(8) Consists of certain income tax adjustments, including foreign income tax reserve releases and discrete tax impacts resulting from the Spin-Off and separation from GE and for the six months ended June 30, 2025, includes tax impacts of the NMP acquisition.

* Non-GAAP financial measure.

Adjusted Earnings Per Share*

(In dollars, except shares outstanding presented in millions)

	For the three months ended June 30			For the six months ended June 30		
Unaudited	**2026**	**2025**	**$ change**	**2026**	**2025**	**$ change**
Diluted earnings per share	**$ 1.24**	**$ 1.06**	**$ 0.18**	**$ 2.08**	**$ 2.29**	**$ (0.20)**
Add: Non-operating benefit (income) costs	(0.10)	(0.16)		(0.21)	(0.32)	
Add: Restructuring costs(1)	0.06	0.04		0.17	0.09	
Add: Acquisition and disposition-related charges (benefits)(2)	0.02	0.02		0.10	0.03	
Add: Spin-Off and separation costs and other adjustments(3)	(0.01)	0.01		(0.01)	0.07	
Add: (Gain) loss on business and asset dispositions(4)	—	0.01		—	(0.01)	
Add: Amortization of acquisition-related intangible assets	0.13	0.09		0.24	0.16	
Add: Investment revaluation (gain) loss(5)	—	0.00		0.02	(0.20)	
Less: Tariff refunds(6)	0.23	—		0.23	—	
Add: Tax effect of reconciling items(7)	0.02	(0.00)		(0.02)	(0.00)	
Add: Spin-Off and other tax adjustments(8)	—	—		(0.02)	(0.04)	
Adjusted earnings per share*	**$ 1.13**	**$ 1.06**	**$ 0.07**	**$ 2.12**	**$ 2.07**	**$ 0.05**
Diluted weighted-average shares outstanding	**454**	**458**		**456**	**459**	

(1) Consists of severance, facility closures, and other charges associated with restructuring programs.
(2) Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions.
(3) Costs and other adjustments related to the Spin-Off and separation from GE, including system implementations, audit and advisory fees, legal entity separation, Founders Grant equity awards, separation agreements with GE, and other one-time costs. For the six months ended June 30, 2025, an adjustment is included to eliminate the associated impact on Net (income) loss attributable to noncontrolling interests for applicable costs that impact earnings attributable to noncontrolling interests.
(4) Consists of gains and losses resulting from the sale of assets and investments.
(5) Primarily relates to valuation adjustments for equity investments and for the six months ended June 30, 2025, includes the impact from the revaluation of our existing 50% interest in NMP as part of the acquisition transaction.
(6) Consists of the pre-tax impact of refunds pertaining to IEEPA tariffs incurred in the year ended December 31, 2025. The associated tax effect is presented on the Tax effect of reconciling items line. The net of tax impact of tariff refunds is $0.18 for the three and six months ended June 30, 2026.
(7) The tax effect of reconciling items is calculated using the statutory tax rate, taking into consideration the nature of the items and the relevant taxing jurisdiction.
(8) Consists of certain income tax adjustments, including foreign income tax reserve releases and discrete tax impacts resulting from the Spin-Off and separation from GE and for the six months ended June 30, 2025, includes tax impacts of the NMP acquisition.

* Non-GAAP financial measure.

Adjusted Tax Expense* and Adjusted ETR*

($ in millions)

	For the three months ended June 30		For the six months ended June 30	
Unaudited	**2026**	**2025**	**2026**	**2025**
Benefit (provision) for income taxes	**$ (119)**	**$ (113)**	**$ (213)**	**$ (216)**
Add: Tax effect of reconciling items[(1)]	11	(1)	(8)	(1)
Add: Spin-Off and other tax adjustments[(2)]	—	—	(7)	(18)
Adjusted tax expense*	**$ (108)**	**$ (114)**	**$ (229)**	**$ (235)**
Effective tax rate	**17.2%**	**18.4%**	**17.8%**	**16.6%**
Adjusted effective tax rate*	**17.1%**	**18.5%**	**18.6%**	**19.3%**

(1) The tax effect of reconciling items is calculated using the statutory tax rate, taking into consideration the nature of the items and the relevant taxing jurisdiction.

(2) Consists of certain income tax adjustments, including foreign income tax reserve releases and discrete tax impacts resulting from the Spin-Off and separation from GE and for the six months ended June 30, 2025, includes tax impacts of the NMP acquisition.

* Non-GAAP financial measure.

Free Cash Flow*

($ in millions)

	For the three months ended June 30			For the six months ended June 30		
Unaudited	**2026**	**2025**	**% change**	**2026**	**2025**	**% change**
Cash from (used for) operating activities	**$ 168**	**$ 94**	**78.5 %**	**$ 458**	**$ 344**	**33.0 %**
Add: Additions to PP&E and internal-use software	(100)	(87)		(278)	(238)	
Add: Dispositions of PP&E	—	—		—	—	
Free cash flow*	**$ 68**	**$ 7**	**835.5 %**	**$ 180**	**$ 106**	**70.0 %**

*Non-GAAP financial measure.

Non-GAAP P&L Reconciliations - 2Q 2026

($ in millions)

Unaudited	GAAP Reported	Restructuring costs(1)	Acquisition and disposition-related charges (benefits)(2)	Spin-Off and separation costs and other adjustments (3)	(Gain) loss on business and asset dispositions(4)	Amortization of acquisition-related intangible assets	Investment revaluation (gain) loss(5)	Tariff Refund(6)	Non-Operating benefit (income) costs	Tax effect of reconciling items(7)	Spin-Off and other tax adjustments (8)	Non-GAAP Results*
Total revenues	**$ 5,295**											**$ 5,295**
Cost of revenues	3,115	(3)	—	—		(51)		106				3,167
Gross profit	**2,180**	**3**	**—**	**—**	**—**	**51**	**—**	**(106)**	**—**	**—**	**—**	**2,128**
Selling, general, and administrative	1,118	(24)	(9)	—		(10)						1,075
Research and development	323		(2)	—								320
Operating income	**739**	**27**	**11**	**—**	**—**	**61**	**—**	**(106)**	**—**	**—**	**—**	**732**
Other (income) expense - net	(22)	—	—	5	—		—					(17)
Interest and other financial charges - net	114											114
Non-operating benefit (income) costs	(45)								45			—
Benefit (provision) for income taxes	(119)									11	—	(108)
Net (income) loss attributable to NCI	(13)											(13)
Net income attributable to GE HealthCare	**$ 561**	**$ 27**	**$ 11**	**$ (5)**	**$ —**	**$ 61**	**$ —**	**$ (106)**	**$ (45)**	**$ 11**	**$ —**	**$ 515**
Gross profit margin	**41.2 %**											**40.2 %**

(1) Consists of severance, facility closures, and other charges associated with restructuring programs.

(2) Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions.

(3) Costs and other adjustments related to the Spin-Off and separation from GE, including system implementations, audit and advisory fees, legal entity separation, Founders Grant equity awards, separation agreements with GE, and other one-time costs.

(4) Consists of gains and losses resulting from the sale of assets and investments.

(5) Primarily relates to valuation adjustments for equity investments.

(6) Consists of the pre-tax impact of refunds pertaining to IEEPA tariffs incurred in the year ended December 31, 2025. The associated tax effect is presented on the Tax effect of reconciling items line. The net of tax impact of tariff refunds is $81 million for the three months ended June 30, 2026.

(7) The tax effect of reconciling items is calculated using the statutory tax rate, taking into consideration the nature of the items and the relevant taxing jurisdiction.

(8) Consists of certain income tax adjustments, including foreign income tax reserve releases and discrete tax impacts resulting from the Spin-Off and separation from GE.

* Non-GAAP financial measure.

Non-GAAP P&L Reconciliations - 2Q 2025

($ in millions)

Unaudited	GAAP Reported	Restructuring costs[1]	Acquisition and disposition-related charges (benefits)[2]	Spin-Off and separation costs and other adjustments[3]	(Gain) loss on business and asset dispositions[4]	Amortization of acquisition-related intangible assets	Investment revaluation (gain) loss[5]	Non-Operating benefit (income) costs	Tax effect of reconciling items[6]	Spin-Off and other tax adjustments[7]	Non-GAAP Results*
Total revenues	**$ 5,007**										**$ 5,007**
Cost of revenues	3,022	(7)	—	(1)		(34)					2,981
Gross profit	**1,985**	**7**	**—**	**1**	**—**	**34**	**—**	**—**	**—**	**—**	**2,026**
Selling, general, and administrative	1,029	(11)	(7)	(4)		(7)					1,001
Research and development	302		—	(1)							301
Operating income	**654**	**18**	**7**	**5**	**—**	**40**	**—**	**—**	**—**	**—**	**724**
Other (income) expense - net	1	—	—	—	(5)		(1)				(4)
Interest and other financial charges - net	113										113
Non-operating benefit (income) costs	(73)							73			—
Benefit (provision) for income taxes	(113)								(1)	—	(114)
Net (income) loss attributable to NCI	(14)										(14)
Net income attributable to GE HealthCare	**$ 486**	**$ 18**	**$ 7**	**$ 5**	**$ 5**	**$ 40**	**$ 1**	**$ (73)**	**$ (1)**	**$ —**	**$ 487**
Gross profit margin	**39.6 %**										**40.5 %**

(1) Consists of severance, facility closures, and other charges associated with restructuring programs.
(2) Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions.
(3) Costs and other adjustments related to the Spin-Off and separation from GE, including system implementations, audit and advisory fees, legal entity separation, Founders Grant equity awards, separation agreements with GE, and other one-time costs.
(4) Consists of gains and losses resulting from the sale of assets and investments.
(5) Primarily relates to valuation adjustments for equity investments and for the six months ended June 30, 2025, includes the impact from the revaluation of our existing 50% interest in NMP as part of the acquisition transaction.
(6) The tax effect of reconciling items is calculated using the statutory tax rate, taking into consideration the nature of the items and the relevant taxing jurisdiction.
(7) Consists of certain income tax adjustments, including discrete tax impacts resulting from the Spin-Off and separation from GE.

* Non-GAAP financial measure.

Non-GAAP P&L Reconciliations - 1H 2026

($ in millions)

Unaudited	GAAP Reported	Restructuring costs(1)	Acquisition and disposition-related charges (benefits)(2)	Spin-Off and separation costs and other adjustments (3)	(Gain) loss on business and asset dispositions(4)	Amortization of acquisition-related intangible assets	Investment revaluation (gain) loss(5)	Tariff Refund(6)	Non-Operating benefit (income) costs	Tax effect of reconciling items(7)	Spin-Off and other tax adjustments (8)	Non-GAAP Results*
Total revenues	**$ 10,425**											**$ 10,425**
Cost of revenues	6,269	(19)	(1)	—		(92)		106				6,263
Gross profit	**4,157**	**19**	**1**	**—**	**—**	**92**	**—**	**(106)**	**—**	**—**	**—**	**4,162**
Selling, general, and administrative	2,235	(56)	(42)	(2)		(16)		—				2,119
Research and development	668		(3)	—								665
Operating income	**1,254**	**76**	**46**	**2**	**—**	**108**	**—**	**(106)**	**—**	**—**	**—**	**1,379**
Other (income) expense - net	(58)	—	—	4	—		(8)					(62)
Interest and other financial charges - net	210											210
Non-operating benefit (income) costs	(96)								96			—
Benefit (provision) for income taxes	(213)									(8)	(7)	(229)
Net (income) loss attributable to NCI	(35)			—								(35)
Net income attributable to GE HealthCare	**$ 950**	**$ 76**	**$ 46**	**$ (2)**	**$ —**	**$ 108**	**$ 8**	**$ (106)**	**$ (96)**	**$ (8)**	**$ (7)**	**$ 967**
Gross profit margin	**39.9 %**											**39.9 %**

(1) Consists of severance, facility closures, and other charges associated with restructuring programs.
(2) Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions.
(3) Costs and other adjustments incurred in the Spin-Off and separation from GE, including system implementations, audit and advisory fees, legal entity separation, Founders Grant equity awards, separation agreements with GE, and other one-time costs.
(4) Consists of gains and losses resulting from the sale of assets and investments.
(5) Primarily relates to valuation adjustments for equity investments.
(6) Consists of the pre-tax impact of refunds pertaining to IEEPA tariffs incurred in the year ended December 31, 2025. The associated tax effect is presented on the Tax effect of reconciling items line. The net of tax impact of tariff refunds is $81 million for the six months ended June 30, 2026.
(7) The tax effect of reconciling items is calculated using the statutory tax rate, taking into consideration the nature of the items and the relevant taxing jurisdiction.
(8) Consists of certain income tax adjustments, including discrete tax impacts resulting from the Spin-Off and separation from GE.

* Non-GAAP financial measure.

Non-GAAP P&L Reconciliations - 1H 2025

($ in millions)

Unaudited	GAAP Reported	Restructuring costs[1]	Acquisition and disposition-related charges (benefits)[2]	Spin-Off and separation costs and other adjustments[3]	(Gain) loss on business and asset dispositions[4]	Amortization of acquisition-related intangible assets	Investment revaluation (gain) loss[5]	Non-Operating benefit (income) costs	Tax effect of reconciling items[6]	Spin-Off and other tax adjustments[7]	Non-GAAP Results*
Total revenues	**$ 9,784**										**$ 9,784**
Cost of revenues	5,787	(10)		(3)		(66)					5,708
Gross profit	**3,997**	**10**	**—**	**3**	**—**	**66**	**—**	**—**	**—**	**—**	**4,076**
Selling, general, and administrative	2,069	(30)	(15)	(16)		(9)					1,998
Research and development	646		—	(1)							644
Operating income	**1,283**	**40**	**15**	**21**	**—**	**75**	**—**	**—**	**—**	**—**	**1,434**
Other (income) expense - net	(98)	—	—	(8)	5		92				(10)
Interest and other financial charges - net	224										224
Non-operating benefit (income) costs	(148)							148			—
Benefit (provision) for income taxes	(216)								(1)	(18)	(235)
Net (income) loss attributable to NCI	(39)			5							(34)
Net income attributable to GE HealthCare	**$ 1,049**	**$ 40**	**$ 15**	**$ 34**	**$ (5)**	**$ 75**	**$ (92)**	**$ (148)**	**$ (1)**	**$ (18)**	**$ 951**
Gross profit margin	**40.9 %**										**41.7 %**

(1) Consists of severance, facility closures, and other charges associated with restructuring programs.

(2) Consists of legal, consulting, and other transaction and integration fees, and adjustments to contingent consideration, as well as other purchase accounting related charges and other costs directly related to the transactions.

(3) Costs and other adjustments related to the Spin-Off and separation from GE, including system implementations, audit and advisory fees, legal entity separation, Founders Grant equity awards, separation agreements with GE, and other one-time costs. For the six months ended June 30, 2025, an adjustment is included to eliminate the associated impact on Net (income) loss attributable to noncontrolling interests for applicable costs that impact earnings attributable to noncontrolling interests.

(4) Consists of gains and losses resulting from the sale of assets and investments.

(5) Primarily relates to valuation adjustments for equity investments and for the six months ended June 30, 2025, includes the impact from the revaluation of our existing 50% interest in NMP as part of the acquisition transaction.

(6) The tax effect of reconciling items is calculated using the statutory tax rate, taking into consideration the nature of the items and the relevant taxing jurisdiction.

(7) Consists of certain income tax adjustments, including foreign income tax reserve releases and discrete tax impacts resulting from the Spin-Off and separation from GE and for the six months ended June 30, 2025, includes tax impacts of the NMP acquisition.

* Non-GAAP financial measure.

Acronyms

AI	Artificial Intelligence
AIS	Advanced Imaging Solutions
bps	Basis points
CE	Conformité Européenne
CT	Computed Tomography
EBIT	Earnings Before Interest and Taxes
EPS	Earnings Per Share
ETR	Effective Tax Rate
EU	European Union
FDA	Food and Drug Administration
FX	Foreign Exchange
MI	Molecular Imaging
NMP	Nihon Medi-Physics
NPIs	New Product Introductions
PCS	Patient Care Solutions
PDx	Pharmaceutical Diagnostics
PP&E	Property, Plant, and Equipment
SaaS	Software as a Service
YoY	Year-over-Year

Definitions

Backlog	The estimated revenue expected from customer contracts that are partially or fully unperformed including amounts deferred in contract liabilities; contracts, or portions thereof, that provide the customer with the right to cancel or terminate without incurring a substantive penalty; and lease contracts
Book-to-Bill	Total orders divided by total revenues within a given financial period (e.g., quarter or FY)
Capital Expenditures	Capital Expenditures represent Additions to property, plant and equipment and internal-use software included in the Condensed Consolidated Statements of Cash Flows
Free cash flow conversion*	Free cash flow* divided by Adjusted net income*
Innovation investment	Includes Research and development expense plus engineering costs for design follow-through on new product introductions and key product lifecycle maintenance subsequent to the initial product launch reported within cost of revenues
NPI Vitality	Defined as percentage of product revenue received in AIS and PCS segments for products introduced in the past three years
Orders	Contractual commitments with customers to provide specified goods or services for an agreed upon price
Organic orders growth	Rate of change period-over-period of contractual commitments with customers to provide specified goods or services for an agreed upon price, and excluding the effects of: (1) recent acquisitions and dispositions with less than a full year of comparable orders; and (2) foreign currency exchange rate fluctuations in order to present orders on a constant currency basis
Past due backlog	Orders that were promised for delivery by a certain date but have not yet been fulfilled
Products	Sales of medical equipment, contrast agents (PDx), software licenses (excludes hosting/SaaS), Options and Upgrades
Services	Maintenance and repair services for equipment, training, parts, software hosting (Software as a Service (SaaS))

GE HealthCare

*Non-GAAP financial measure

Non-GAAP Financial Measures

The non-GAAP financial measures presented in this presentation are supplemental measures of GE HealthCare's performance and its liquidity that the Company believes will help investors understand its financial condition, cash flows, and operating results, and assess its future prospects. When read in conjunction with the Company's U.S. GAAP results, these non-GAAP financial measures provide a baseline for analyzing trends in GE HealthCare's underlying businesses and can be used by management as one basis for making financial, operational, and planning decisions. Descriptions of the reported non-GAAP measures are included below.

The Company reports **Organic revenue and Organic revenue growth rate** to provide management and investors with additional understanding and visibility into the underlying revenue trends of its established, ongoing operations, as well as provide insights into overall demand for our products and services. To calculate these measures, the Company excludes the effect of acquisitions, dispositions, and foreign currency rate fluctuations.

The Company reports **Adjusted gross profit, Adjusted gross profit margin, EBIT, Adjusted EBIT, Adjusted EBIT margin, Adjusted net income, and Adjusted earnings per share** to provide management and investors with an additional understanding of its business by highlighting the results from ongoing operations and the underlying profitability factors, on a normalized basis. To calculate these measures the Company excludes, and reflects in the detailed reconciliations elsewhere in this presentation, the following adjustments as applicable: Interest and other financial charges – net, Net (income) loss attributable to noncontrolling interests, Non-operating benefit (income) costs, Benefit (provision) for income taxes and certain tax related adjustments, and certain non-recurring and/or non-cash items. GE HealthCare may from time to time consider excluding other non-recurring items to enhance comparability between periods. Adjusted gross profit margin and Adjusted EBIT margin are calculated by taking Adjusted gross profit or Adjusted EBIT, divided by Total revenues for the same period.

The Company reports **Adjusted tax expense and Adjusted ETR** to provide management and investors with a better understanding of the normalized tax rate applicable to the business and provide more consistent comparability across periods. Adjusted tax expense excludes the income tax related to the pre-tax income adjustments included as part of Adjusted net income and certain income tax adjustments, such as adjustments to deferred tax assets or liabilities. The Company may from time to time consider excluding other non-recurring tax items to enhance comparability between periods. Adjusted ETR is Adjusted tax expense divided by income before income taxes less the pre-tax income adjustments referenced above.

The Company reports **Free cash flow and Free cash flow conversion** to provide management and investors with an important measure of the ability to generate cash on a normalized basis and provide insight into the Company's flexibility to allocate capital. Free cash flow is Cash from (used for) operating activities – continuing operations including cash flows related to the additions and dispositions of PP&E and additions of internal-use software. Free cash flow does not represent residual cash flows available for discretionary expenditures, due to the fact that the measure does not deduct the capital required for debt repayments. Free cash flow conversion is calculated by taking Free cash flow divided by Adjusted net income.

Management recognizes that these non-GAAP financial measures have limitations, including that they may be calculated differently by other companies or may be used under different circumstances or for different purposes. In order to compensate for the discussed limitations, management does not consider these measures in isolation from or as alternatives to the comparable financial measures determined in accordance with U.S. GAAP. The detailed reconciliations of each non-GAAP financial measure to the most directly comparable U.S. GAAP financial measure are provided elsewhere in this presentation, and no single financial measure should be relied on to evaluate our business.

Non-GAAP Financial Measures in Outlook

GE HealthCare calculates forward-looking non-GAAP financial measures, including Organic revenue growth, Adjusted EBIT margin, Adjusted ETR, Adjusted EPS, and Free cash flow based on internal forecasts that omit certain amounts that would be included in U.S. GAAP financial measures. GE HealthCare does not provide reconciliations of these forward-looking non-GAAP financial measures to the respective U.S. GAAP metrics as it is unable to predict with reasonable certainty and without unreasonable effort certain items such as the impact of changes in currency exchange rates, impacts associated with business acquisitions or dispositions, timing and magnitude of restructuring activities, and revaluation of strategic investments, amongst other items. The timing and amounts of these items are uncertain and could have a substantial impact on GE HealthCare’s results in accordance with U.S. GAAP.